A nanoparticle stays in joints 23 days and cuts friction by over half.

Joint injuries can trigger post-traumatic osteoarthritispost-traumatic osteoarthritisA type of joint disease that starts after an injury, where cartilage breaks down and causes pain and stiffness.. Treating this early by injecting medicine directly into the joint is difficult because the body clears drugs away too quickly, the joint lacks lubrication, and inflammation keeps shifting. To solve this, researchers designed a multi-tasking nanoparticlenanoparticleA very tiny particle that can deliver medicine directly to specific cells or tissues. called PDMI. It acts like a Trojan horse. Its watery outer shell stops immune cells from clearing it out and lowers joint friction. Inside, chemical groups soak up damaging molecules called reactive oxygen species, which then triggers the particle to release a soothing drug named icariinicariinA plant compound that reduces inflammation and protects cartilage.. In tests, PDMI cut friction in artificial joint fluid and stayed inside the joint far longer than free dye. In cartilage cells, it calmed inflammation and protected cell energy centers. Finally, a single injection in rats with joint injuries protected cartilage, lessened abnormal bone growth, and reduced joint damage scores by more than 80%.

Why it matters

For individuals who suffer joint injuries, current treatments are limited because injected drugs clear out within hours and inflammation persists. This nanoparticle could change that: it remains in the joint for over three weeks, reduces friction by half, and releases anti-inflammatory medicine only when needed. In rats, a single shot prevented cartilage damage and abnormal bone changes, offering a path toward preventing post-traumatic osteoarthritis in humans.

Questions answered